Events & Presentations

Presentations

a scientist with vials being tested

Earnings Presentations

Oct 30, 2024
Q3 2024 Biogen Earnings Presentation
Aug 01, 2024
Q2 2024 Biogen Earnings Presentation
Apr 24, 2024
Q1 2024 Biogen Earnings Presentation
Feb 13, 2024
Q4 and Full Year 2023 Biogen Earnings Presentation
Nov 08, 2023
Q3 2023 Biogen Earnings Presentation

Investor R&D Day 2021

Sep 21, 2021
Biogen 2021 Investor R&D Day
Sep 21, 2021
Biogen Digital Health
Sep 21, 2021
Advancements in Research
Sep 21, 2021
Alzheimer’s Disease Research Portfolio
Sep 21, 2021
Biogen Gene Therapy
Sep 21, 2021
Biomarkers
Sep 21, 2021
Biotherapeutics and Medicinal Sciences at Biogen
Sep 21, 2021
Human Genetics
Sep 21, 2021
Movement Disorders at Biogen
Sep 21, 2021
MS Portfolio

Conference and Other Investor Presentations

Jul 28, 2023
Proposed Acquisition of Reata Pharmaceuticals, Inc.
Dec 06, 2022
Biogen and Sage Zuranolone Webcast Presentation
Jan 13, 2022
Biogen Analyst Q&A Call
Jun 08, 2021
Biogen ADUHELM Launch
Oct 22, 2019
Aducanumab Update Presentation
Jun 05, 2019
Biogen ALS & R&D Portfolio Webcast Presentation
Mar 04, 2019
Biogen Planned Acquisition of Nightstar Therapeutics
Dec 12, 2018
Biogen MS & R&D Webcast Presentation
Jun 28, 2018
Biogen on R&D Progress Targeting Stroke

Medical and Scientific Conference Presentations

Jul 22, 2018
24-Month Analysis of APOE ε4 Carriers in PRIME, a Randomized Phase 1B Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab
Jul 22, 2018
24-Month Analysis of Change From Baseline In Clinical Dementia Rating Scale Cognitive and Functional Domains in PRIME, A Randomized Phase 1b Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab
Apr 22, 2018
Aducanumab Titration Dosing Regimen: 24-Month Interim Analysis from PRIME, a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients With Prodromal or Mild Alzheimer’s Disease
Apr 22, 2018
Aducanumab 36-Month Data From PRIME: A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients With Prodromal or Mild Alzheimer’s Disease
Mar 15, 2018
The Importance of Early Identification and Treatment of Alzheimer’s Disease
Apr 25, 2017
NUSINERSEN NURTURE Interim Results (Presentation) Ph3 AAN 2017
AAN, April 25, 2017
Apr 25, 2017
NUSINERSEN CHERISH Final Results (Poster & Presentation) Ph3 AAN 2017
AAN, April 25, 2017
Apr 24, 2017
NUSINERSEN ENDEAR Final Results (Presentation) Ph3 AAN 2017
AAN, April 24, 2017

Annual Stockholder Presentation

June 15, 2022
Biogen Annual Stockholder Presentation 2022

Hemophilia Spin-off Presentations

January 6, 2017
Bioverativ (BIVV) Analyst Day Presentation
May 3, 2016
Hemophilia Spin-off Presentation
Stockholder Communications icon

Stockholder Communications

E-mail Alerts icon

E-mail Alerts

FAQs icon

FAQs

Learn more about our Events & Presentations